ING Groep NV Grows Stock Position in Cencora, Inc. $COR

ING Groep NV lifted its stake in Cencora, Inc. (NYSE:COR) by 16.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 196,696 shares of the company’s stock after buying an additional 28,132 shares during the period. ING Groep NV’s holdings in Cencora were worth $66,434,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of COR. Oakworth Capital Inc. purchased a new position in Cencora during the 4th quarter valued at about $26,000. Elyxium Wealth LLC purchased a new position in Cencora during the 4th quarter valued at about $27,000. Archer Investment Corp increased its holdings in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares during the period. IAG Wealth Partners LLC purchased a new position in Cencora during the 3rd quarter valued at about $30,000. Finally, Caitlin John LLC purchased a new position in Cencora during the 3rd quarter valued at about $31,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Cencora stock opened at $274.94 on Friday. The stock’s 50 day simple moving average is $292.70 and its two-hundred day simple moving average is $330.55. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The stock has a market cap of $53.49 billion, a price-to-earnings ratio of 21.08, a PEG ratio of 1.48 and a beta of 0.59. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora announced that its Board of Directors has approved a share repurchase program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is presently 18.40%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. William Blair assumed coverage on Cencora in a report on Tuesday, April 28th. They set a “market perform” rating on the stock. Robert W. Baird reduced their price target on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Wells Fargo & Company reduced their price target on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th. Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Finally, Weiss Ratings downgraded Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.